Finding Balance through Innovation
2013 Medical Innovation Summit
October 14-16, 2013
 |
Laurence Berlowitz Tarrant, PhD Chief Scientific Officer and Founder Histogenics Laurence Berlowitz Tarrant received a PhD in genetics from the University of California, Berkeley in 1965 and was an NSF Fellow at the MRC Epigenetics Research Group, Edinburgh, studying with C.H. Waddington and Max Birnstiel. He had an internationally recognized academic career, culminating in a Professorship at New York University, and commenced his career in industry in 1984 at the interface of cell biology and the surface chemistry of materials at the Norton Company. His work was among the earliest identifying materials bioactivity as a key to successful tissue regeneration. He founded ITMA Ltd, which rapidly transferred academic technologies to important commercial product development and made major contributions to dental, bone, and cartilage product development. In 2000 he became President, Chief Executive Officer, and Founder of Histogenics Corporation, a company dedicated to regenerating healthy cartilage, whose technology represents a synergy of cell biology, materials science, and advanced engineering. He is the co-inventor of Histogenics first product, NeoCart® and its second product VeriCart™. Currently, Histogenics is in the midst of phase III clinical trials on its unique autologous tissue implant, NeoCart. Dr. Berlowitz Tarrant remains in the company as Founder and Chief Scientific Officer, and has responsibility for his latest inventions, including On-demand NeoCart, utilizing allogeneic pericytes and bioactive scaffolds to form cartilage implants ex-vivo for immediate use. He is also chief consultant to Exogenesis corporation on adapting its semi-conductor developed, non-additive, nanosurface techniques to cell and tissue growth. Return to Speakers Page |
Cleveland Clinic
© All Rights Reserved